We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+19.58%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$161M
AUM Growth
+$20.9M
Cap. Flow
-$8.51M
Cap. Flow %
-5.29%
Top 10 Hldgs %
48.45%
Holding
88
New
12
Increased
11
Reduced
19
Closed
14

Top Buys

Rank Stock Value
1
DXCM icon
DexCom
DXCM
+$4.07M
2
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$3.08M
3
CBAY
Cymabay Therapeutics
CBAY
+$2.81M
4
ACHN
Achillion Pharmaceuticals
ACHN
+$2.01M
5
TVRD
Tvardi Therapeutics
TVRD
+$1.31M

Top Sells

Rank Stock Value
1
LOXO
Loxo Oncology, Inc
LOXO
+$3.22M
2
SPNC
Spectranetics Corp
SPNC
+$2.15M
3
SGMO
SANGAMO THERAPEUTICS INC
SGMO
+$1.98M
4
CLLS
Cellectis
CLLS
+$1.97M
5
IMMU
Immunomedics Inc
IMMU
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 80.09%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARQL
51
DELISTED
Arqule Inc
ARQL
$475K 0.29%
427,478
-357,030
-46% -$411K
MASI
52
DELISTED
Masimo
MASI
$433K 0.27%
5,000
+750
+18% +$66.3K
KDMN
53
DELISTED
Kadmon Holdings, Inc.
KDMN
$419K 0.26%
+125,000
New +$357K
DCPH
54
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$380K 0.24%
+20,000
New +$366K
NTUS
55
DELISTED
Natus Medical Inc
NTUS
$296K 0.18%
7,900
– –
NEOS
56
DELISTED
Neos Therapeutics, Inc
NEOS
$252K 0.16%
27,500
-182,373
-87% -$1.39M
BLCM
57
DELISTED
Bellicum Pharmaceuticals, Inc.
BLCM
$231K 0.14%
2,000
– –
PDSB icon
58
PDS Biotechnology
PDSB
$37M
$208K 0.13%
970
– –
ATNM icon
59
Actinium Pharmaceuticals
ATNM
$27.1M
$192K 0.12%
+11,100
New +$244K
ISEE
60
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$141K 0.09%
+50,000
New +$135K
DMK
61
DELISTED
DMK Pharmaceuticals Corporation Common Stock
DMK
$127K 0.08%
349
– –
FSTX
62
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$110K 0.07%
1,627
+1,227
+307% +$70.3K
CTMX icon
63
CytomX Therapeutics
CTMX
$697M
$107K 0.07%
+5,900
New +$92.1K
SRRA
64
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
$68K 0.04%
1,100
-5,525
-83% -$324K
SLS icon
65
SELLAS Life Sciences
SLS
$1.99B
$16K 0.01%
31
– –
AFMD
66
DELISTED
Affimed
AFMD
– –
-9,250
Closed -$190K
ANAB icon
67
AnaptysBio
ANAB
$1.53B
– –
-5,500
Closed -$132K
BLRX
68
BioLineRX
BLRX
$12.3M
– –
-1,634
Closed -$828K
CLLS
69
Cellectis
CLLS
$285M
– –
-76,404
Closed -$1.97M
RCKT icon
70
Rocket Pharmaceuticals
RCKT
$337M
– –
-59,284
Closed -$451K
SGMO
71
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-225,000
Closed -$1.98M
TNDM icon
72
Tandem Diabetes Care
TNDM
$1.25B
– –
-72,429
Closed -$579K
MTVA
73
MetaVia Inc
MTVA
$7.33M
– –
0
– -$394K
EIGR
74
DELISTED
Eiger BioPharmaceuticals, Inc.
EIGR
– –
-1,199
Closed -$284K
HSTO
75
DELISTED
Histogen Inc. Common Stock
HSTO
– –
-250
Closed -$288K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
CPW
Cove Private Wealth Oyster Bay Cove, New York $440M AUM 27.56% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
DWML
Decker Wealth Management LLC Nashville, Tennessee $441M AUM

DAFNA Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, DAFNA Capital Management held 88 positions worth $161M, up 15% from $140M the previous quarter. Its ten largest holdings account for 48% of the portfolio.

DAFNA Capital Management withdrew a net $8.51M in Q3 2017, closing 14 positions and reducing 19 holdings. Its most notable exit was Spectranetics Corp, an estimated $2.15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, up from 80% a quarter earlier.

Against the trend, DAFNA Capital Management opened a new position in DexCom worth $2.81M.

  • DAFNA Capital Management's largest Q3 2017 buy was DexCom: 230,000 shares worth $2.81M.
  • DAFNA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $3.08M increase.
  • DAFNA Capital Management's biggest Q3 2017 reduction was Loxo Oncology, Inc, cutting an estimated $3.22M.
  • DAFNA Capital Management fully exited Spectranetics Corp in Q3 2017, selling an estimated $2.15M.
  • DAFNA Capital Management's ten largest holdings make up 48% of its $161M portfolio in Q3 2017.
  • DAFNA Capital Management opened 12 new positions and closed 14 in Q3 2017.
  • DAFNA Capital Management's portfolio value rose 15% quarter-over-quarter to $161M.

Based on DAFNA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.